Opko Health Financials
OPK Stock | USD 1.48 0.03 2.07% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Debt Equity Ratio | 0.2 | 0.21 |
|
| |||||
Current Ratio | 1.69 | 1.78 |
|
|
The essential information of the day-to-day investment outlook for Opko Health includes many different criteria found on its balance sheet. An individual investor should monitor Opko Health's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Opko Health.
Net Income |
|
Opko | Select Account or Indicator |
Opko Health Stock Summary
Opko Health competes with Caredx, Castle Biosciences, Twist Bioscience, Biodesix, and Natera. OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company was founded in 1991 and is headquartered in Miami, Florida. Opko Health operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 5767 people.Foreign Associate | Israel |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US68375N1037 |
CUSIP | 68375N103 301610101 23282G105 |
Location | Florida; U.S.A |
Business Address | 4400 Biscayne Boulevard, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.opko.com |
Phone | 305 575 4100 |
Currency | USD - US Dollar |
Opko Health Key Financial Ratios
Return On Equity | -0.0939 | ||||
Profit Margin | (0.19) % | ||||
Operating Margin | (0.62) % | ||||
Price To Sales | 1.40 X | ||||
Revenue | 863.5 M |
Opko Health Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 2.5B | 2.4B | 2.2B | 2.0B | 2.3B | 2.4B | |
Other Current Liab | 222.6M | 219.1M | 95.5M | 85.9M | 98.8M | 64.5M | |
Net Debt | 149.8M | 53.2M | 60.3M | 230.7M | 265.3M | 278.5M | |
Retained Earnings | (1.5B) | (1.5B) | (1.8B) | (2.0B) | (1.8B) | (1.7B) | |
Accounts Payable | 100.9M | 82.0M | 61.6M | 69.7M | 80.1M | 84.1M | |
Cash | 72.2M | 134.7M | 153.2M | 95.9M | 110.3M | 63.6M | |
Total Liab | 801.5M | 714.6M | 605.7M | 622.5M | 715.9M | 751.6M | |
Total Current Assets | 523.2M | 823M | 394.5M | 309.5M | 355.9M | 183.8M | |
Intangible Assets | 1.3B | 1.1B | 790.9M | 935.3M | 1.1B | 572.8M | |
Other Current Assets | 16.4M | 336.2M | 18.7M | 17.7M | 20.4M | 19.3M | |
Short Term Debt | 36.2M | 28.6M | 51.0M | 43.1M | 49.6M | 52.1M | |
Common Stock | 6.7M | 6.9M | 7.8M | 7.8M | 9.0M | 9.4M | |
Other Liab | 153.8M | 204M | 196.7M | 126.4M | 145.4M | 142.0M | |
Other Assets | 7.0M | 653.7M | 465.9M | 981.9M | 1.1B | 1.2B | |
Long Term Debt | 225.8M | 187.9M | 219.5M | 222.0M | 255.3M | 268.1M | |
Net Receivables | 302.3M | 265.6M | 148.6M | 130.2M | 149.7M | 117.8M | |
Inventory | 132.3M | 86.5M | 74.1M | 65.7M | 75.6M | 42.4M | |
Good Will | 680.6M | 520.6M | 595.9M | 598.3M | 688.0M | 421.7M | |
Net Tangible Assets | 413.9M | 515.9M | 574.3M | 770.7M | 886.3M | 930.6M | |
Capital Surpluse | 3.0B | 3.1B | 3.2B | 3.2B | 3.7B | 2.5B |
Opko Health Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Interest Expense | 21.9M | 18.9M | 12.1M | 13.5M | 15.5M | 16.3M | |
Total Revenue | 1.4B | 1.8B | 1.0B | 863.5M | 993.0M | 1.0B | |
Gross Profit | 541M | 581.5M | 288.2M | 318.1M | 365.8M | 384.1M | |
Operating Income | 57.7M | (47.7M) | (246.2M) | (157.0M) | (141.3M) | (134.3M) | |
Ebit | 53.7M | 4.9M | (379.5M) | (170.8M) | (153.7M) | (146.0M) | |
Ebitda | 139.1M | 83.6M | (270.8M) | (65.5M) | (59.0M) | (56.0M) | |
Cost Of Revenue | 894.4M | 1.2B | 716M | 545.4M | 627.2M | 658.5M | |
Net Income | 30.6M | (29.5M) | (328M) | (188.9M) | (170.0M) | (161.5M) | |
Income Tax Expense | 17.6M | 15.5M | (63.5M) | 4.4M | 4.0M | 4.2M | |
Research Development | 75.3M | 76.8M | 73.9M | 89.6M | 103.0M | 108.2M | |
Income Before Tax | 48.7M | (14M) | (391.5M) | (184.3M) | (165.9M) | (157.6M) | |
Tax Provision | 17.6M | 15.5M | (63.5M) | (6.5M) | (7.5M) | (7.9M) | |
Interest Income | 152K | 28K | 2.0M | 4.2M | 3.8M | 5.1M | |
Net Interest Income | (21.8M) | (18.9M) | (10.1M) | (9.1M) | (8.2M) | (8.6M) |
Opko Health Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Change In Cash | (13.2M) | 62.5M | 18.5M | (57.3M) | (51.6M) | (49.0M) | |
Free Cash Flow | 5.8M | 6.2M | (119.8M) | (44.5M) | (40.0M) | (42.0M) | |
Depreciation | 85.4M | 78.7M | 108.7M | 105.3M | 121.1M | 127.1M | |
Other Non Cash Items | (3.5M) | (13.5M) | 137.8M | 22.0M | 25.3M | 26.9M | |
Capital Expenditures | 33.7M | 32.2M | 24.6M | 16.3M | 18.7M | 9.4M | |
Net Income | 30.6M | (30.1M) | (328.4M) | (188.9M) | (170.0M) | (161.5M) | |
End Period Cash Flow | 72.2M | 134.7M | 153.2M | 95.9M | 110.3M | 63.7M | |
Change To Netincome | 11.0M | 104.8M | 19.9M | 9.3M | 10.7M | 10.2M | |
Change To Inventory | (77.6M) | 30.7M | 13.7M | 15.2M | 17.5M | 18.4M | |
Investments | 15.1M | 6.1M | 91.0M | (24.7M) | (28.3M) | (26.9M) | |
Change Receivables | 20.4M | 7.4M | (150.4M) | 5.2M | 4.7M | 4.9M | |
Net Borrowings | 47.2M | 99.2M | (35.8M) | (11.4M) | (10.3M) | (9.8M) |
Opko Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Opko Health's current stock value. Our valuation model uses many indicators to compare Opko Health value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Opko Health competition to find correlations between indicators driving Opko Health's intrinsic value. More Info.Opko Health is regarded fourth in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Opko Health's Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Opko Health by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Opko Health Systematic Risk
Opko Health's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Opko Health volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was seven with a total number of output elements of fifty-four. The Beta measures systematic risk based on how returns on Opko Health correlated with the market. If Beta is less than 0 Opko Health generally moves in the opposite direction as compared to the market. If Opko Health Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Opko Health is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Opko Health is generally in the same direction as the market. If Beta > 1 Opko Health moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Opko Health Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Opko Health's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Opko Health growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Opko Health January 4, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Opko Health help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Opko Health. We use our internally-developed statistical techniques to arrive at the intrinsic value of Opko Health based on widely used predictive technical indicators. In general, we focus on analyzing Opko Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Opko Health's daily price indicators and compare them against related drivers.
Downside Deviation | 2.17 | |||
Information Ratio | (0) | |||
Maximum Drawdown | 11.67 | |||
Value At Risk | (3.11) | |||
Potential Upside | 3.29 |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Opko Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Opko Stock please use our How to buy in Opko Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opko Health. If investors know Opko will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opko Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.191 | Earnings Share (0.19) | Revenue Per Share | Quarterly Revenue Growth (0.03) | Return On Assets |
The market value of Opko Health is measured differently than its book value, which is the value of Opko that is recorded on the company's balance sheet. Investors also form their own opinion of Opko Health's value that differs from its market value or its book value, called intrinsic value, which is Opko Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opko Health's market value can be influenced by many factors that don't directly affect Opko Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opko Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Opko Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opko Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.